Apr'20 | Apr'21 | Apr'22 | Apr'23 | Apr'24 | |
---|---|---|---|---|---|
FCF to Net Income | 101.1% | 100.0% | 75.5% | 91.1% | 93.8% |
Apr'20 | Apr'21 | Apr'22 | Apr'23 | Apr'24 | |
---|---|---|---|---|---|
% growth | 0.1 0.0% | 0.0 (60.1%) | 0.0 (43.9%) | 0.0 (64.2%) | 0.0 261.2% |
Cost of Goods Sold (COGS) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
% margin | 0.0 27.6% | 0.0 58.3% | 0.0 45.1% | 0.0 45.7% | 0.0 67.3% |
Operating Expenses | 3.8 | 2.6 | 4.7 | 6.1 | 6.3 |
Research & Development Expenses (R&D) | 2.0 | 1.7 | 3.0 | 2.5 | 2.9 |
Selling, General & Administrative Expenses (SG&A) | 1.8 | 0.9 | 1.7 | 3.7 | 3.4 |
% margin | (3.8) (5,949.0%) | (2.6) (10,030.2%) | (4.7) (32,765.6%) | (6.1) (118,698.3%) | (6.3) (33,902.0%) |
Interest Income | 0.0 | 0.1 | 0.4 | 0.2 | 0.0 |
Interest Expense | 0.0 | 0.1 | 0.4 | 0.2 | 0.4 |
Pre-tax Income | (3.8) | (2.5) | (4.8) | (6.4) | (6.6) |
% effective tax rate | 0.0 (0.6%) | 0.1 (5.3%) | (0.3) 5.2% | 484.5 (7,624.8%) | 0.0 0.0% |
% margin | (3.8) (5,973.4%) | (2.6) (10,081.1%) | (4.6) (31,851.8%) | (490.9) (9,531,151.3%) | (6.6) (35,511.9%) |
EPS | (115.69) | (77.89) | (137.94) | (6,173.88) | (18.74) |
Diluted EPS | (115.69) | (77.89) | (137.94) | (6,173.88) | (18.74) |
% margin | (3.7) (5,834.2%) | (2.3) (8,928.7%) | (4.4) (30,822.2%) | (6.1) (118,139.8%) | (6.2) (33,096.7%) |
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
As of today, Microsoft Corp's last 12-month FCF to Net Income is 101.7%, based on the financial report for Oct 31, 2024 (Q4’2024). The average annual FCF to Net Income for Heart Test Laboratories, Inc. have been 127.4% over the past three years, and 95.5% over the past five years.
As of today, Heart Test Laboratories, Inc.'s FCF to Net Income is 101.7%, which is higher than industry median of 80.2%. It indicates that Heart Test Laboratories, Inc.'s FCF to Net Income is Good.